-
1
-
-
84906847366
-
Final Report of the Phase I/II Clinical Trial of the E75 (nelipepimut-S) Vaccine with Booster Inoculations to Prevent Disease Recurrence in High-Risk Breast Cancer Patients
-
Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S and Peoples GE. Final Report of the Phase I/II Clinical Trial of the E75 (nelipepimut-S) Vaccine with Booster Inoculations to Prevent Disease Recurrence in High-Risk Breast Cancer Patients. Ann Oncol. 2014; 25:1735-1742.
-
(2014)
Ann Oncol
, vol.25
, pp. 1735-1742
-
-
Mittendorf, E.A.1
Clifton, G.T.2
Holmes, J.P.3
Schneble, E.4
van Echo, D.5
Ponniah, S.6
Peoples, G.E.7
-
2
-
-
0029555751
-
Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction
-
Fisk B, Savary C, Hudson JM, O'Brian CA, Murray JL, Wharton JT and Ioannides CG. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction. J Immunother Emphasis Tumor Immunol. 1995; 18:197-209.
-
(1995)
J Immunother Emphasis Tumor Immunol
, vol.18
, pp. 197-209
-
-
Fisk, B.1
Savary, C.2
Hudson, J.M.3
O'Brian, C.A.4
Murray, J.L.5
Wharton, J.T.6
Ioannides, C.G.7
-
3
-
-
0028857587
-
Breast and ovarian cancerspecific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
-
Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I and Eberlein TJ. Breast and ovarian cancerspecific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A. 1995; 92:432-436.
-
(1995)
Proc Natl Acad Sci U S A
, vol.92
, pp. 432-436
-
-
Peoples, G.E.1
Goedegebuure, P.S.2
Smith, R.3
Linehan, D.C.4
Yoshino, I.5
Eberlein, T.J.6
-
4
-
-
0033579435
-
Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide
-
Kuhns JJ, Batalia MA, Yan S and Collins EJ. Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide. J Biol Chem. 1999; 274:36422-36427.
-
(1999)
J Biol Chem
, vol.274
, pp. 36422-36427
-
-
Kuhns, J.J.1
Batalia, M.A.2
Yan, S.3
Collins, E.J.4
-
5
-
-
0034331218
-
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
-
Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L and Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000; 96:3102-3108.
-
(2000)
Blood
, vol.96
, pp. 3102-3108
-
-
Brossart, P.1
Wirths, S.2
Stuhler, G.3
Reichardt, V.L.4
Kanz, L.5
Brugger, W.6
-
6
-
-
33646886582
-
Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial
-
Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S and Peoples GE. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer. 2006; 106:2309-2317.
-
(2006)
Cancer
, vol.106
, pp. 2309-2317
-
-
Mittendorf, E.A.1
Storrer, C.E.2
Foley, R.J.3
Harris, K.4
Jama, Y.5
Shriver, C.D.6
Ponniah, S.7
Peoples, G.E.8
-
7
-
-
75649136936
-
Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04
-
Carmichael MG, Benavides LC, Holmes JP, Gates JD, Mittendorf EA, Ponniah S and Peoples GE. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer. 2010; 116:292-301.
-
(2010)
Cancer
, vol.116
, pp. 292-301
-
-
Carmichael, M.G.1
Benavides, L.C.2
Holmes, J.P.3
Gates, J.D.4
Mittendorf, E.A.5
Ponniah, S.6
Peoples, G.E.7
-
8
-
-
84977100884
-
Primary analysis of a prospective, randomized, singleblinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence
-
Mar 30 [Epub ahead of print]
-
Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M and Peoples GE. Primary analysis of a prospective, randomized, singleblinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol. 2016 Mar 30 [Epub ahead of print].
-
(2016)
Ann Oncol
-
-
Mittendorf, E.A.1
Ardavanis, A.2
Symanowski, J.3
Murray, J.L.4
Shumway, N.M.5
Litton, J.K.6
Hale, D.F.7
Perez, S.A.8
Anastasopoulou, E.A.9
Pistamaltzian, N.F.10
Ponniah, S.11
Baxevanis, C.N.12
von Hofe, E.13
Papamichail, M.14
Peoples, G.E.15
-
9
-
-
84860700518
-
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
-
Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S and Peoples GE. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2012; 118:2594-2602.
-
(2012)
Cancer
, vol.118
, pp. 2594-2602
-
-
Mittendorf, E.A.1
Clifton, G.T.2
Holmes, J.P.3
Clive, K.S.4
Patil, R.5
Benavides, L.C.6
Gates, J.D.7
Sears, A.K.8
Stojadinovic, A.9
Ponniah, S.10
Peoples, G.E.11
-
10
-
-
0034234934
-
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
-
Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH and Jaffee EM. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 2000; 60:3569-3576.
-
(2000)
Cancer Res
, vol.60
, pp. 3569-3576
-
-
Reilly, R.T.1
Gottlieb, M.B.2
Ercolini, A.M.3
Machiels, J.P.4
Kane, C.E.5
Okoye, F.I.6
Muller, W.J.7
Dixon, K.H.8
Jaffee, E.M.9
-
11
-
-
0035116901
-
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors
-
Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D and Jaffee EM. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 2001; 61:880-883.
-
(2001)
Cancer Res
, vol.61
, pp. 880-883
-
-
Reilly, R.T.1
Machiels, J.P.2
Emens, L.A.3
Ercolini, A.M.4
Okoye, F.I.5
Lei, R.Y.6
Weintraub, D.7
Jaffee, E.M.8
-
12
-
-
0043136619
-
HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice
-
Wolpoe ME, Lutz ER, Ercolini AM, Murata S, Ivie SE, Garrett ES, Emens LA, Jaffee EM and Reilly RT. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol. 2003; 171:2161-2169.
-
(2003)
J Immunol
, vol.171
, pp. 2161-2169
-
-
Wolpoe, M.E.1
Lutz, E.R.2
Ercolini, A.M.3
Murata, S.4
Ivie, S.E.5
Garrett, E.S.6
Emens, L.A.7
Jaffee, E.M.8
Reilly, R.T.9
-
13
-
-
0034684659
-
CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo
-
den Haan JM, Lehar SM and Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med. 2000; 192:1685-1696.
-
(2000)
J Exp Med
, vol.192
, pp. 1685-1696
-
-
den Haan, J.M.1
Lehar, S.M.2
Bevan, M.J.3
-
14
-
-
78049427830
-
Tumor antigentargeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape
-
Ferris RL, Jaffee EM and Ferrone S. Tumor antigentargeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010; 28:4390-4399.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4390-4399
-
-
Ferris, R.L.1
Jaffee, E.M.2
Ferrone, S.3
-
15
-
-
34548842227
-
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy
-
Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL and Clynes R. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res. 2007; 13:5133-5143.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 5133-5143
-
-
Taylor, C.1
Hershman, D.2
Shah, N.3
Suciu-Foca, N.4
Petrylak, D.P.5
Taub, R.6
Vahdat, L.7
Cheng, B.8
Pegram, M.9
Knutson, K.L.10
Clynes, R.11
-
16
-
-
84994177697
-
Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831
-
Knutson KL, Perez EA, Ballman KV, Erskine CL, Fox N, McCarl C-A, Norton N, Sumrall SV, Northfelt DW and Tan W. (2013). Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831. J Clin Oncol (Meeting Abstracts), pp. 522.
-
(2013)
J Clin Oncol (Meeting Abstracts
, pp. 522
-
-
Knutson, K.L.1
Perez, E.A.2
Ballman, K.V.3
Erskine, C.L.4
Fox, N.5
McCarl, C.-A.6
Norton, N.7
Sumrall, S.V.8
Northfelt, D.W.9
Tan, W.10
-
17
-
-
70350435441
-
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer
-
Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, dela Rosa C, Tietje K, Link J, Waisman J and Salazar LG. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009; 27:4685-4692.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4685-4692
-
-
Disis, M.L.1
Wallace, D.R.2
Gooley, T.A.3
Dang, Y.4
Slota, M.5
Lu, H.6
Coveler, A.L.7
Childs, J.S.8
Higgins, D.M.9
Fintak, P.A.10
dela Rosa, C.11
Tietje, K.12
Link, J.13
Waisman, J.14
Salazar, L.G.15
-
18
-
-
84968829167
-
Results of a phase Ib trial of combination immunotherapy with HER2-derived peptide vaccine GP2+GM-CSF and trastuzumab in breast cancer patient
-
Clifton GT, Stassen SE, Arrington KL, Ponniah S, Greene JM, Schneble EJ, Gall V, Peoples GE, Mittendorf EA. Results of a phase Ib trial of combination immunotherapy with HER2-derived peptide vaccine GP2+GM-CSF and trastuzumab in breast cancer patients. [Abstract 37] Ann Surc Oncol. 2015; 22:S18.
-
(2015)
Ann Surc Oncol
, vol.22
, pp. S18
-
-
Clifton, G.T.1
Stassen, S.E.2
Arrington, K.L.3
Ponniah, S.4
Greene, J.M.5
Schneble, E.J.6
Gall, V.7
Peoples, G.E.8
Mittendorf, E.A.9
-
19
-
-
79251503953
-
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
-
Holmes JP, Clifton GT, Patil R, Benavides LC, Gates JD, Stojadinovic A, Mittendorf EA, Ponniah S and Peoples GE. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2011; 117:463-471.
-
(2011)
Cancer
, vol.117
, pp. 463-471
-
-
Holmes, J.P.1
Clifton, G.T.2
Patil, R.3
Benavides, L.C.4
Gates, J.D.5
Stojadinovic, A.6
Mittendorf, E.A.7
Ponniah, S.8
Peoples, G.E.9
-
20
-
-
0016842811
-
Editorial: Measurement of delayed skin-test responses
-
Sokal JE. Editorial: Measurement of delayed skin-test responses. N Engl J Med. 1975; 293:501-502.
-
(1975)
N Engl J Med
, vol.293
, pp. 501-502
-
-
Sokal, J.E.1
|